Ares Financial Consulting’s Travere Therapeutics TVTX Stock Holding History

Ares Financial Consulting’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78K	Buy	+49	New	+$2.17K	﹤0.01%	834

Other funds holding TVTX

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PIP

Palisades Investment Partners Santa Monica, California $352M AUM 76.79% 1-Year Est. Return

Ares Financial Consulting's TVTX Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 49 shares worth $2.78K. The stake represents ﹤0.01% of the portfolio and ranks #834 among its holdings.

96 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Ares Financial Consulting held 49 shares of Travere Therapeutics worth $2.78K as of Q2 2026.
Travere Therapeutics was a new Ares Financial Consulting position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #834 holding.
96 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.